Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted delivery of an antibody-mutant human endostatin fusion protein results in enhanced antitumor efficacy.

Molecular cancer therapeutics - 1 Apr 2011

Shin Seung-Uon, Cho Hyun-Mi, Merchan Jaime, Zhang Jin, Kovacs Krisztina, Jing Yawu, Ramakrishnan Sundaram, Rosenblatt Joseph D

Abstract excerpt

The antiangiogenic protein endostatin showed considerable preclinical antitumor activity, but limited efficacy in phase I/II trials. Prior studies using an anti-HER2 antibody-murine endostatin fusion showed enhanced antitumor activity compared to anti-HER2 antibody or endostatin given alone, or in combination. We have generated two anti-HER2 human endostatin fusion proteins by fusing either wild-type or a mutant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Antibodies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Area Under Curve

Share to Mammary Neoplasms, Experimental

Share to Mice, SCID

Share to Receptor, ErbB-2

Share to Tumor Burden

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 21393427
DOI: 10.1158/1535-7163.MCT-10-0804

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted delivery of an antibody-mutant human endostatin fusion protein results in enhanced antitumor efficacy.PMID 21393427Read ↗

Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy.Semantic proximity Read ↗

Phase I Study of Recombinant Human Endostatin in Patients With Advanced Solid TumorsSemantic proximity Read ↗

Human endostatin-derived synthetic peptides possess potent antiangiogenic properties in vitro and in vivoSemantic proximity Read ↗

Inhibition of the mammary carcinoma angiogenic switch in C3(1)/SV40 transgenic mice by a mutated form of human endostatin.Semantic proximity Read ↗

N-/C-terminal deleted mutant of human endostatin efficiently acts as an anti-angiogenic and anti-tumorigenic agent.Semantic proximity Read ↗

Anti-angiogenic effects of a mutant endostatin: a new prospect for treating retinal and choroidal neovascularization.Semantic proximity Read ↗

Biological evaluation of new TEM1 targeting recombinant antibodies for radioimmunotherapy: In vitro, in vivo and in silico studies.Semantic proximity Read ↗

Adeno-associated virus-mediated delivery of a mutant endostatin in combination with carboplatin treatment inhibits orthotopic growth of ovarian cancer and improves long-term survival.Semantic proximity Read ↗

A high‐affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo‐vasculature <i>in vivo</i>Semantic proximity Read ↗

The clinical potential of antiangiogenic fragments of extracellular matrix proteinsSemantic proximity Read ↗

Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanismsSemantic proximity Read ↗

A novel humanized Frizzled-7-targeting antibody enhances antitumor effects of Bevacizumab against triple-negative breast cancer via blocking Wnt/β-catenin signaling pathwaySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.